Oncologia Medica Ospedale di Prato
Welcome,         Profile    Billing    Logout  
 5 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Biganzoli, Laura
POLAR, NCT03820830 / 2018-003553-19: Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

Recruiting
3
400
Europe
Palbociclib 125mg, Ibrance, PD-0332991, Standard endocrine therapy
ETOP IBCSG Partners Foundation, Pfizer
Breast Cancer Recurrent
12/24
11/26
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
IMPORTANT, NCT06044623: Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients

Recruiting
3
495
Europe
CDK 4/6 inhibitors, Endocrine therapy
Region Örebro County, University of Patras, University of Florence, Azienda USL Toscana Centro, Helsinki University Central Hospital, Institute for Medical Technology Assessment - the Netherlands, Security Labs Consulting Limited, Circular Economy Foundation, Universidad Nacional de Educación a Distancia, Hellenic Cooperative Oncology Group, University Hospital, Akershus, Uppsala County Council, Sweden, Hospital Clinic of Barcelona, Phaze Clinical Research & Pharma Consulting, Bröstcancerförbundet, Eunomia Ltd, University of Applied Sciences and Arts Northwestern Switzerland, CareAcross Ltd, Örebro University, Sweden
Metastatic Breast Cancer, Advanced Breast Cancer, Quality of Life, Toxicity, Older Patients
04/28
04/31
TOUCH, NCT03644186 / 2017-005067-40: To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer

Completed
2
144
Europe
Paclitaxel, Paclitaxel Sandoz, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Palbociclib, Ibrance, Letrozole, Femara
ETOP IBCSG Partners Foundation, Pfizer, Hoffmann-La Roche
Breast Cancer, Estrogen Receptor Positive Tumor, HER2-positive Breast Cancer
01/23
04/23
FACILE, NCT03944434 / 2018-002514-12: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer

Active, not recruiting
2
116
Europe
Ribociclib, Kisqali, Aromatase Inhibitors, non steroideal, Femara, Arimidex, LHRH agonist, Triptorelin, Leuprolide, Goserelin
Fondazione Sandro Pitigliani, Novartis
Breast Cancer
12/24
11/25
PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Recruiting
2
220
Europe
Giredestrant, Triptorelin, Anastrozole
ETOP IBCSG Partners Foundation, Hoffmann-La Roche
Breast Cancer
06/26
06/26
NCT06363812: Probability of OncotypeDx to Reallocate as Low or High Risk of Recurrence Breast Cancer Patients With Uncertain Biology

Active, not recruiting
N/A
258
Europe
Fondazione Sandro Pitigliani, Genomic Health®, Inc., Istituto Toscano Tumori
Breast Cancer
05/21
12/24

Download Options